My list of expected/hoped for 2025 Milestones second half 25FY:
New European MDR approval by Feb
Completion of percutaneous Pancosil trial by February and announcement of outcomes by March/April
TGA (re)submission by April
Start enrolment into GBA trial by June
First commercial sales in Germany and UK by June
Completion of enrolment for TRIPP by June.
On target for AUD$1million sales 25FY after release 3 rd quarter results in May
Commissioning of Sydney plant by June
If these happen by June 30 then the share price should be above the 0.9 cent trigger for options uptake.
If all exercised or underwritten, company raises 17 million.
- Forums
- ASX - By Stock
- Ann: First Patient in Australia Randomised in TRIPP-FFX Trial
OSL
oncosil medical ltd
Add to My Watchlist
6.84%
!
$1.02

My list of expected/hoped for 2025 Milestones second half 25FY:...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.02 |
Change
0.065(6.84%) |
Mkt cap ! $14.43M |
Open | High | Low | Value | Volume |
$1.00 | $1.03 | 96.0¢ | $23.22K | 23.59K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9576 | 95.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.02 | 14282 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9576 | 0.955 |
1 | 15628 | 0.950 |
1 | 819 | 0.940 |
1 | 627 | 0.920 |
1 | 23 | 0.910 |
Price($) | Vol. | No. |
---|---|---|
1.015 | 14282 | 1 |
1.020 | 1042 | 1 |
1.030 | 27 | 1 |
1.050 | 25000 | 1 |
1.075 | 1879 | 1 |
Last trade - 14.07pm 18/06/2025 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online